Tigermed and Frontage Laboratories Complete Strategic Investment Agreement
Hangzhou Tigermed Consulting and Frontage Laboratories announced completion of the previously announced investment agreement
Hangzhou Tigermed Consulting and Frontage Laboratories announced completion of the previously announced investment agreement, following approval by the China Securities and Regulatory Commission. Tigermed, a provider of outsourced clinical development services across China and Asia Pacific regions to the pharmaceutical and medical device industries has acquired a majority position in the ownership of Frontage, a bioanalysis, preclinical studies, early phase clinical studies and product development services provider for biopharmaceutical organizations. The partnership establishes the presence of Tigermed's global clinical trial network. Frontage will continue to operate independently, and will retain its existing company name, management team and operations facilities.
Read the full release here.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
